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High mobility group box protein 1 (HMGB1) acts as an endogenous danger molecule that is released from
necrotic cells and activated macrophages. We have previously shown that peptide Hp91, whose sequence
corresponds to an area within the B-Box domain of HMGB1, activates dendritic cells (DCs) and acts as an adjuvant in vivo.
Here we investigated the underlying mechanisms of Hp91-mediated DC activation. Hp91-induced secretion of IL-6
was dependent on clathrin- and dynamin-driven endocytosis of Hp91 and mediated through a MyD88- and
TLR4-dependent pathway involving p38 MAPK and NFκB. Endosomal TLR4 has been shown to activate the
MyD88-independent interferon pathway. Hp91-induced activation of pIRF3 and IL-6 secretion was reduced in
IFNαβR knockout DCs, suggesting an amplification loop via the IFNαβR. These findings elucidate the mechanisms
by which Hp91 acts as immunostimulatory peptide and may serve as a guide for the future development of
synthetic Th1-type peptide adjuvants for vaccines.Introduction
The adaptive immune response is commonly initiated via
pathogen-associated molecular patterns (PAMPs) that are
recognized by Toll-like receptors (TLRs) [1]. Dendritic
cells (DC) are central for the initiation of adaptive im-
mune responses and are activated by exogenous PAMPs
such as lipopolysaccharides (LPS), CpG, or poly(I:C) [2] as
well as endogenous signals of tissue and cell damage,
sometimes referred to as alarmins or danger signals [3,4].
Alarmins can take the form of inflammatory cytokines
secreted by cells proximal to the site of injury [5] or in-
ternal components of damaged cells. Evidence for the
latter includes reports that necrotic cell lysates, more
specifically heat shock proteins (HSPs) and high mobil-
ity group box protein 1 (HMGB1) in the lysates, can in-
duce DC maturation [6-8].
HMGB1 was originally described as a nuclear protein
that facilitates DNA bending and stabilizes nucleosome
formation [9]. HMGB1 contains three domains, includ-
ing two homologous DNA binding motifs termed A-* Correspondence: bmessmer@ucsd.edu
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and a negatively charged C-terminus [10,11]. In addition
to the nuclear functions, HMGB1 is secreted by both
macrophages and monocytes after exposure to LPS,
TNF-α or IL-1β [12] and, through a feedback loop, acts
back on monocytes by stimulating the synthesis of add-
itional pro-inflammatory cytokines [13]. More recently,
HMGB1 was identified as an endogenous alarmin, or
damage-associated molecular pattern (DAMP) [3,14].
HMGB1 is released from necrotic cells to trigger inflam-
mation [15] and act as an endogenous adjuvant [16].
Several receptors are implicated in HMGB1 mediated
activation of cells, including the receptor for advanced
glycation end-products (RAGE) [17,18], toll like receptor
2 (TLR2), TLR4 [19-23], TLR9 [24], Mac-1 [25],
syndecan-1 [26,27], receptor-type tyrosine phosphatase-
ζ/β [26,28], and CD24/Siglec-10 [29].
Structure-function studies have revealed that the pro-
inflammatory domain in HMGB1 maps to the B-box
domain, which recapitulates the cytokine activity of
full-length HMGB1 [30,31]. We have previously shown
that a B-box domain derived peptide, named Hp91
acted as a potent maturation stimulus for DCs and in-
duced a cytokine profile typical of a Th1-type responsetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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antigen-specific humoral and cellular immune re-
sponses in vivo [33]. This study explored the mechan-
ism by which Hp91 activates antigen presenting cells by
investigating cellular uptake, receptor dependence, and
signaling pathways. We found that Hp91-induced se-
cretion of IL-6 was mediated through a MyD88/TLR4-
dependent pathway involving p38MAPK and NFκB.
Materials and methods
Animals
Female C57BL/6 mice 8–12 weeks of age were used for ex-
periments. C57BL/6 mice were purchased from Charles
River Laboratories (Boston, MA, USA). TLR4−/− and
IL1R−/− mice were purchased from The Jackson La-
boratories (Bar Harbor, ME, USA). IFNαβR−/− mice
were purchased from B&K Universal (England, UK).
MyD88−/− and TLR7−/− mice were a gift from S.
Akira (Osaka University, Osaka, Japan) and backcrossed
for 10 generations onto the C57BL/6 background. Mice
were bred and maintained at the Moores UCSD Cancer
Center animal facility and all animal studies were ap-
proved by the Institutional Animal Care and Use Com-
mittee of UCSD and were performed in accordance
with the institutional guidelines.
Reagents
The peptides, including Hp91 (DPNAPKRPPSAFFLFCSE),
Hp121 (SIGDVAKKLGEMWNNTAA), scrambled Hp91
(ASLAPPFPNCFDPKSREF), and OVA-I (SIINFEKL) were
all synthesized at GMP facilities by GenScript Corp
(Piscataway, NJ, USA) and CPC Scientific (San Jose, CA,
USA). Peptides were synthesized with an N-terminal bio-
tin, acetyl, or fluorescent tag (Cp488) as indicated in the
figure legends. Peptides were routinely synthesized with
greater than 95% purity. Peptides, reagents, and labware
were endotoxin-free as determined by the manufacturer or
a limulus amoebocyte assay (LAL) (Cambrex Corporation,
East Rutherford, NJ), tested according to manufacturer’s
instructions. Peptides were dissolved in RPMI or PBS for
in vitro and in vivo experiments respectively. Phenylarsine
oxide and chlorpromazine (clathrin-mediated endocytosis
inhibitors), sodium azide (energy-dependent endocytosis in-
hibitor), nystatin (caveolin-mediated endocytosis inhibitor),
latrunculin B (phagocytosis inhibitor), amiloride (micropi-
nocytosis inhibitor), and dynasore (dynamin inhibitor)
were purchased from Sigma-Aldrich as endocytosis inhibi-
tors. The p38 MAPK-specific inhibitor, SB203580, and
the NFκB inhibitor, N-tosyl-L-phenylalanine chloromethyl
ketone (TPCK), were purchased from Sigma-Aldrich. The
MEK1 inhibitor, PD98059, was purchased from Cell
Signaling Technology (Danvers, MA). As many of these
inhibitors required solubilization in DMSO, DMSO was
used as a negative control.Cell lines
The J774 cell line was a gift from Maurizio Zanetti (UCSD)
and was cultured in RPMI 1640 medium (Invitrogen), sup-
plemented with 10 mM HEPES (Invitrogen), penicillin
(100 U/ml), streptomycin (100 μg/ml), L-glutamine (2 mM)
(Invitrogen), and 10% (vol/vol) fetal calf serum (Omega
Scientific, Tarzana, CA). The RAW 264.7 cell line was a
gift from Dong-Er Zang (UCSD) and was cultured as
above, except with 5% (vol/vol) fetal calf serum (Omega).
Generation of human monocyte-derived DCs
Peripheral blood mononuclear cells were isolated from
the blood of normal volunteers over a Ficoll-Hypaque
(Amersham Biosciences, Uppsala, Sweden) density gra-
dient. Anonymous blood samples were purchased from
the San Diego Blood Bank; therefore, no institutional
review board approvals were necessary. To generate
DCs, peripheral blood mononuclear cells were allowed
to adhere to culture plates for 1 h. The non-adherent
cells were washed off, and the adherent cells were cul-
tured in RPMI 1640 medium (Invitrogen) supplemented
with 50 mmol 2-mercaptoethanol (Sigma-Aldrich), 10 mM
HEPES (Invitrogen), penicillin (100 U/ml), streptomycin
(100 μg/ml), L-glutamine (2 mM) (Invitrogen), and either
5% (vol/vol) human AB serum (Gemini Bio Products,
West Sacramento, CA) or 1% (vol/vol) human plasma
(Valley Biomedical, Winchester, VA) and supplemented with
GM-CSF (1000 U/ml) (Bayer HealthCare Pharmaceuticals,
Wayne, New Jersey), and interleukin-4 (100 U/ml) (IL-4;
R&D Systems, Minneapolis, Minnesota) at days 0, 2, and 4.
Immature human DCs (iDCs) were harvested on days 5–7.
Generation of mouse bone marrow-derived DCs
Bone marrow-derived DCs (BM-DCs) were prepared from
C57BL/6 and knockout mice, as described by Inaba et al.
[34] with minor modifications. Briefly, single bone marrow
cell suspensions were obtained from femurs and tibias and
depleted of lymphocytes, granulocytes, and Ia + cells by in-
cubating with a mixture of monoclonal antibodies (mAbs;
anti-CD4, anti-CD8, anti-B220/ CD45R, and anti-Ia) (anti-
body hybridomas were a gift from Ralph Steinman
(Rockefeller)) and low-toxicity rabbit complement (Pel
Freez Biologicals, Rogers, AR) for 60 min at 37°C. Cells
were re-suspended at a concentration of 106 cells/ml in
RPMI 1640 medium (Invitrogen) supplemented with
50 mM 2-mercaptoethanol (Sigma-Aldrich), 10 mM
HEPES (Invitrogen), penicillin (100 U/ml), streptomycin
(100 μg/ml), L-glutamine (2 mM) (Invitrogen), 5% (vol/vol)
fetal calf serum (Omega), and 10 ng/ml recombinant
murine granulocyte-macrophage colony-stimulating factor
(GM-CSF) (J558L GM-CSF-secreting cells were a gift
from Ralph Steinman). Fresh complete medium containing
GM-CSF was added on days 2 and 4 of culture. Cells were
collected for the experiments on days 5–7.
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1x105 immature human DCs were precooled on ice and
subsequently incubated for 30 min on ice with biotinylated-
Hp91 or Hp121 to allow peptide binding. Cells were
washed and then incubated for the indicated time at 37°C.
Cells were cytospun (Shandon Cytospin 2 centrifuge) onto
glass slides, fixed, permeabilized with acetone, and stained
with Streptavidin-Alexa 488 (Invitrogen) to visualize bio-
tinylated peptides and Hoechst 33258 (Invitrogen) to
visualize DNA. Cells were imaged on a Zeiss LSM confocal
microscope.
Binding/uptake studies
For most experiments, iDCs or mouse BM-DCs were pre-
cooled on ice for 30 min, as indicated in the figure leg-
ends. Cells were subsequently incubated for the indicated
times and temperatures in culture medium with biotinyl-
ated peptides. Cells were washed, permeabilized with
Cytofix/Cytoperm (BD Biosciences, Franklin Lakes, NJ),
stained with Streptavidin-Alexa 488 (Invitrogen), and ana-
lyzed by flow cytometry. For experiments with endocytosis
inhibitors, cells were pre-treated for 30 min with the indi-
cated inhibitors or controls prior to incubation with the
biotinylated peptides. For experiments with J774 mouse
macrophages, cells were pre-cooled on ice, pre-treated
with 30 min with the indicated inhibitors, and subse-
quently incubated for 30 min with fluorescently-labeled
Hp91 (Cp488-Hp91). Cells were immediately analyzed by
flow cytometry using the FACSCalibur (Beckon Dickinson,
Franklin Lakes, NJ). Data were analyzed using the FlowJo
software (Tree Star, Inc., Ashland, OR).
Stimulation of DCs
At days 5–7 of culture, DCs were either left untreated or
were stimulated with indicated doses of peptide. For in-
hibition experiments, immature human DCs were pre-
treated with the indicated doses of SB203580, PD98059,
N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), or
DMSO control for 30 min prior to stimulation. For exper-
iments with human DCs, supernatants were collected
48 h after stimulation and the level of IL-6 analyzed by
IL-6 ELISA (eBioscience, Inc. San Diego, CA). For experi-
ments with mouse BM-DCs, supernatants were analyzed
by ELISA (eBioscience), 24 h after stimulation.
Immunizations and splenocyte preparation
Mice were immunized s.c. with 50 μg of OVA-derived
SIINFEKL peptide (OVA-1). The SIINFEKL peptide was
co-administered with PBS, Hp91 (250 μg), or scrambled
Hp91 (250 μg). Peptides were re-suspended in PBS for all
immunizations. Mice were boosted two weeks later and
spleens and blood were collected one week after the final
immunization. Single cell suspensions of splenocytes were
prepared by mechanical disruption and separation througha 70 mm nylon cell strainer (BD Biosciences). Red blood
cells were lysed using ammonium chloride buffer
(Roche Diagnostics, Indianapolis, IN) and the spleno-
cytes were subsequently re-suspended in RPMI 1640
medium (Invitrogen) supplemented with 10 mM HEPES
(Invitrogen), penicillin (100 U/ml), streptomycin (100 μg/ml),
L-glutamine (2 mM) (Invitrogen), and 5% (vol/vol) fetal
calf serum (Omega).
Enzyme-linked immunospot assay
Freshly isolated splenocytes were plated in duplicate
wells in an Immobilon-P (PVDF) bottom enzyme-linked
immunospot (ELISpot) plate (Millipore, Millerica, MA,
USA) precoated with 5 μg/ml monoclonal anti-mouse
IFN-γ antibody (Mabtech, Stockholm, Sweden). Spleno-
cytes were cultured overnight at 37°C with 2.5 μg/ml
SIINFEKL (OVA-I) peptide, 2.5 μg/ml ISQAVHAA-
HAEINEAGR (OVA-II) peptide, 5 μg/ml concanavalin A
positive control (Sigma-Aldrich), or left unstimulated
(medium only). After 18 h, culture supernatants were
collected for cytokine analysis and ELISpot plates were
developed using 1 μg/ml biotinylated anti-mouse IFN-γ
antibody (Mabtech), Streptavidin-HRP, and TMB Sub-
strate (Mabtech). The plate was scanned and the spots
were counted using an automated ELISpot Reader System
(CTL ImmunoSpot, Shaker Heights, OH, USA).
Cytokine Release Assay
Splenocytes were cultured overnight with 2.5 μg/ml
OVA-I peptide, 5 μg/ml concanavalin A positive control
(Sigma-Aldrich), or left unstimulated (media only). After
18 h, cell culture supernatants were collected and ana-
lyzed for the presence of IL-2 by ELISA (eBioscience).
Immunoblotting
Mouse J774 or RAW 264.7 macrophages stimulated with
Hp91 or LPS for 20, 40, or 60 minutes were lysed for 20 mi-
nutes on ice in RIPA lysis buffer (10 mM Tris pH 7.4,
150 mM NaCl, 1% TritonX-100, 0.1% sodium deoxycho-
late, 0.1% sodium dodecylsulfate (SDS), 5 mM EDTA sup-
plemented with 1 mM phenylmethylsulfonyl fluoride, Halt
phosphatase inhibitor (Thermo Fisher Scientific, Rockford,
IL), 1 mM sodium vanadate, 1 mM sodium fluoride, and
complete protease inhibitor cocktail (Roche). Protein con-
centration was determined with the Detergent Compatible
protein assay (Bio-Rad, Hercules, CA). The lysates were
snap-frozen and stored at −80°C. Equal amounts of protein
lysates were separated by gel electrophoresis with the use
of a NuPAGE Novex 4%-12% Bis-Tris Midi Gel (Invitro-
gen) and transferred to polyvinylidene fluoride membranes
(Bio-Rad). Membranes were washed with 1 × TBST (Tris-
Buffered Saline Tween-20) and blocked for 1 hour at room
temperature in 5% milk/TBST. Membranes were probed
overnight for phospho- p38, phospho (p)-interferon
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phosphate dehydrogenase (GAPDH), or β-actin (Cell
Signaling Technology). The next day, membranes were
washed with 1× TBST and incubated with goat anti–
rabbit or anti–mouse horseradish peroxidase–conjugated
secondary antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA) diluted in 5% milk/TBST for 1 h at room
temperature. Antibodies were detected with the use of
either an enhanced chemiluminescence detection kit (GE
Healthcare, Piscataway, NJ) or SuperSignal West Femto
Maximum Sensitivity Substrate (Thermo Fisher Scientific).
In some experiments, cells were pre-treated with the
endocytosis inhibitor Dynasore.
Qualitative real-time PCR
Qualitative real-time PCR (qPCR) was performed in a
Stratagene Mx3005P (Agilent, Santa Clara, CA) for mouse
IFN- α2 and GAPDH. GAPDH was used as an endogenous
standard for normalization of the IFN- α2 gene. Briefly,
1.25 × 105 J774 macrophages/well were serum-starved
overnight in a 96-well flat-bottom plate and stimulated
in duplicate with LPS (10 ng/ml), acetylated Hp91
(200 μg/ml), or left unstimulated (media) for 6 hours.
Cells were harvested and RNA was isolated using TRIzol
as follows: the J774 cell pellets were lysed in approximately
1 ml of TRIzol Reagent (Invitrogen) by repetitive pipetting.
The cleared homogenate solution was incubated for 5 min
at RT, 200 μl of chloroform was added and samples were
shaken for 15 seconds and incubated at RT for an add-
itional 2–3 min. Samples were centrifuged at 12000 × g
for 15 minutes at 4°C. Pellets were washed with 1 ml 75%
RNAse-free ethanol, centrifuged for 7000 × g for 5 min
at 4°C, and the RNA pellets were air dried. DNase was re-
moved from samples using a Turbo DNAfree DNase treat-
ment (Applied Biosystems/Ambion, Austin, TX). cDNA
was synthesized using Superscript III-RT polymerase
(Invitrogen) and related reagents as per the manufacture’s
instructions. qPCR samples were setup using Brilliant II
SYBR Green QPCR Master Mix (Invitrogen) and the
following Q-primers: IFN-α2 (For. 5‘-ACTCTGTGCTT
TCCTCGTGATGCT-3’; Rev. 5‘-ATCCAAAGTCCTGC
CTGTCCTTCA-3’) and GAPDH (For. 5‘- TCACCACC
ATGGAGAAGGC-3’; Rev. 5‘-GCTAACCAGTTGGTG
GTGCA-3’). Primers were purchased from IDT. qPCR
was performed on duplicate samples in a Stratagene
Mx3005P. Amplification product lengths were con-
firmed on a DNA gel. Values are normalized against
GAPDH controls.
Statistical analysis
Data were analyzed for statistical significance using un-
paired or paired Student’s t-test or the Log Rank test.
Statistical analysis was performed using GraphPad soft-
ware version 5.01 for Windows (GraphPad Software, SanDiego, CA, USA). A p value <0.05 was considered statis-
tically significant.
Results
Hp91 amino acid sequence is critical for uptake and
activation of DCs
To gain insight into the mechanism of action of the DC
stimulatory peptide Hp91, we investigated its physical
interaction with DCs. Hp91 was taken up in a dose
dependent manner (Figure 1A), which plateaued be-
tween 10 and 30 minutes (Figure 1B). The control pep-
tide, Hp121, which also corresponds to a sequence
present in HMGB1 and has the same length, a similar
charge, and isoelectric point as Hp91 was not taken up
by DCs and uptake of a scrambled version of Hp91, was
significantly lowered (Figure 1C, 1D and 1E), suggesting
that uptake of Hp91 is sequence specific and not due to
overall charge. Confocal microscopy was used to distin-
guish between cellular binding and uptake and showed
localization of Hp91 inside DCs. The control peptide
Hp121 was not detected inside the cells, even after
30 minutes incubation at 37°C (Figure 1C). Since the
scrambled version of Hp91 interacted with DCs, although
to a much lesser extent than Hp91 (Figure 1D and 1E),
we examined if it had similar immunogenic properties
as Hp91, which as we have previously described poten-
tiates antigen-specific CD8+ T cell immune responses
in vivo [33]. The scrambled version of Hp91 did not
augment OVA-specific CD8+ CTL responses or IL-2
release (Figure 1F and 1G), suggesting that Hp91 func-
tional activity is sequence specific.
Hp91 enters dendritic cells via clathrin-mediated
endocytosis
Hp91 was taken up at 37°C, but not at 16 and 4°C
(Additional file 1: Figure S1), indicating that the uptake
occurred via an energy dependent process, i.e. endocytosis.
This was further supported by a significant inhibition of up-
take of a fluorescently labeled version of Hp91 (Cp488) by
sodium azide, which inhibits energy-dependent endocytosis
(data not shown). The endocytic pathways include phago-
cytosis, macropinocytosis, clathrin-mediated endocytosis,
and lipid-raft/caveolin-mediated endocytosis. The mechan-
ism involved in the Hp91 uptake was determined using
specific inhibitors of these endocytosis pathways. Latruncu-
lin B (LatB), a specific phagocytosis inhibitor, did not re-
duce uptake of Hp91 (Figure 2A), whereas it completely
abrogated uptake of the control Dextran FITC (data not
shown). Phenylarsine oxide and chlorpromazine, inhibitors
of clathrin-mediated endocytosis, significantly reduced the
uptake of Hp91, suggesting that uptake occurs via clathrin-
mediated endocytosis (Figure 2B). In contrast, no effects
were seen on the uptake of Hp91 for the lipid-raft/
caveolin-mediated endocytosis inhibitor, nystatin, or the
Figure 1 (See legend on next page.)
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Figure 1 Hp91 uptake by DCs is dose, time, and sequence dependent. (A) Immature human DCs were pre-incubated on ice for 30 min, then
incubated with biotinylated-Hp91 (0, 10, or 100 μg/ml) for 30 min at 37°C. Cells were permeabilized with Cytofix/Cytoperm, stained with
Streptavidin-Alexa 488, and analyzed by flow cytometry. The results shown is one representative experiment (N = 6). (B) Immature human DCs
were incubated with 100 μg/ml biotinylated Hp91 for 10 or 30 minutes, permeabilized, stained, and analyzed as above. Results shown are
mean (±SEM) of N = 4. (C) Pre-cooled immature human DCs (iDCs) were incubated on ice for 30 min with 200 μg/ml biotinylated Hp91 or
Hp121 to allow peptide binding, washed, then incubated for 15, or 30 additional min at 37°C. Cells were cytospun, fixed, permeabilized, and
stained with Streptavidin-Alexa 488 to visualize biotinylated peptides (Green) and Hoechst DNA stain (Blue). Cells were imaged on a Zeiss LSM
confocal microscope. Data shown is one representative experiment of N = 3. (D-E) Immature human DCs were pre-cooled on ice for 30 min,
then incubated with media only, biotinylated-Hp91, biotinylated-Hp121, or biotinylated-scrambled Hp91 (“Scramble”) at 200 μg/ml for 30 min
at 37°C. Cells were permeabilized, stained, and analyzed by flow cytometry as above. (D) is mean (±SEM) for N = 3 and (E) is one representative experiment.
*p < 0.05 compared to medium; Student’s t-test. (F, G) Mice were immunized with OVA-I peptide in PBS with Hp91 or scrambled Hp91 peptide (250 μg).
(F) Freshly isolated splenocytes from the immunized mice were examined in an OVA IFN-γ ELISpot assay. (G) Supernatants were collected and analyzed for
IL-2 secretion by ELISA. The data shown is mean (±SEM) for 5–10 mice/group. *p < 0.05 between groups; Student’s t-test.
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ing that the uptake was not occurring via neither lipid
rafts nor macropinocytosis. These data show that the
major mechanism for Hp91 uptake into DCs occurs via a
clathrin coated pit dependent manner.
Hp91-mediated activation of DCs in vitro is dependent on
TLR4, MyD88, and IFNαβR
Several receptors have been implicated in mediating the
responses to HMGB1, including TLR4 [19-22,24,26].
Since our data show that receptor-mediated uptake, i.e.
clathrin-mediated endocytosis, is clearly involved in
the uptake of Hp91 (Figure 2B), we sought to identify
the receptor(s) involved in Hp91-induced activation of
DCs. Bone marrow (BM)-DCs generated from wild typeFigure 2 Uptake of Hp91 is via clathrin-mediated endocytosis. (A) Imm
Latrunculin B or medium only for 30 min before incubation with biotinylat
stained with Streptavidin-Alexa 488, and analyzed by flow cytometry. Data
for 30 min with media only (Med), DMSO (D) = solvent control, the clathrin
chlorpromazine (CP) at 100 μM, the energy-dependent endocytosis inhib
inhibitor nystatin (NY) at 20 μM, or the micropinocytosis inhibitor amiloride (A
30 min. Cells were permeabilized, stained, and analyzed by flow cytometry as
control; Student’s t-test.and various knockout mice were exposed to Hp91. IL-6
secretion was significantly reduced in BM-DCs generated
from MyD88−/−, TLR4−/−, and IFNαβR−/− knockout
mice (Figure 3A), whereas IL-6 production from BM-DCs
generated from TLR7−/− and IL-1R−/− knockout mice
was comparable to wild type cells (Figure 3A), indicating
that TLR4/MyD88 and IFNαβR are involved in the activa-
tion of DC by Hp91.
Hp91-mediated activation of mouse antigen presenting
cells is clathrin- and dynamin-dependent
Since ligand engaged TLR4 is endocytosed in a dynamin-
dependent manner for downstream signaling in macro-
phages exposed to LPS [35], we evaluated if Hp91 signals
through a similar TLR4 mechanism as dynamin is part ofature human DCs were pre-treated with the phagocytosis inhibitor
ed-Hp91 for 30 min. Cells were permeabilized with Cytofix/Cytoperm,
are mean (±SEM) of N = 5. (B) Immature human DCs were pre-treated
-mediated endocytosis inhibitors phenylarsine oxide (PAO) at 2 μM or
itor sodium azide (SA) at 10 mM, the caveolin-mediated endocytosis
M) at 2 mM before incubation with biotinylated Hp91 (200 μg/ml) for
above. Results are mean (±SEM) of N = 3. **p < 0.01 compared to DMSO
Figure 3 TLR4, MyD88, and MyD88-dependent and -independent pathways are necessary for Hp91-mediated activation of antigen
presenting cells. (A) BM-DCs from wild type (WT) or knockout mice were exposed to 200 μg/ml Hp91. Supernatants were analyzed for IL-6 by
ELISA. Results are mean (±SEM) for N = 3-5. (B) J774 macrophages were stimulated for indicated times with 200 μg/ml Hp91, 10 ng/ml LPS or left
untreated (M). Lysates were analyzed for p-p38 by WB. Blots were probed with anti-p-p38, anti-p38, and anti-GAPDH antibodies. One of N=4. (C)
J774 macrophages were pretreated with media (Med), DMSO control (D), Dynasore (DYN) 80 μM, phenylarsine oxide (PAO) 2 μM or chlorpromazine (CP)
100 μM before incubation with 200 μg/ml Cp488-labeled Hp91 for 30 min. Cells were analyzed by flow cytometry. Results are mean (±SEM), N=4. (D) J774
macrophages were pretreated with DMSO control (D), SB203580 (SB) 20 μM, PD98059 (PD) 20 μM, TPCK 20 μM, Dynasore (DYN) 80 μM, phenylarsine oxide
(PAO) 2 μM, or chlorpromazine (CP) 100 μM then exposed to Hp91. Supernatants were analyzed for IL-6 by ELISA. Data are mean (±SEM), N=3. (E) RAW
264.7 macrophages were pretreated with medium, DMSO control, or Dynasore (DYN) 80 μM prior to stimulation for indicated times with Hp91
(200 μg/ml), LPS (10 ng/ml) or media. Cell lysates were analyzed for p-IRF3. Immunoblots were probed with anti-p-IRF3, anti-IRF3, and anti-β-
actin antibodies. (F) cDNA from stimulated J774 cells were evaluated for IFN-α2 mRNA by qPCR. Values are normalized against endogenous
GAPDH controls, in duplicate. (G) Wildtype or MyD88−/− knockout mice were immunized with SIINFEKL peptide in PBS with or without Hp91.
Splenocytes from immunized mice were cultured with SIINFEKL peptide (2.5 μg/ml). The number of IFN-γ-secreting cells was determined 18 h
later. Data are mean (±SEM), 5–10 mice/group. *p < 0.05; Student’s t-test.
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dynamin-dependent endocytosis inhibitor, dynasore, sig-
nificantly inhibited uptake of Hp91 by macrophages
(Figure 3C), which is in agreement with the finding re-
ported for LPS [35]. The clathrin-mediated endocytosisinhibitor phenylarsine oxide also inhibited uptake of Hp91
by macrophages (Figure 3C). In addition, blocking uptake
of Hp91 via dynamin or clathrin mediated endocytosis sig-
nificantly reduced IL-6 secretion (Figure 3D). Since a re-
duction in Hp91-mediated IL-6 secretion was observed in
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and NF-κB inhibitors (Figure 4), we evaluated if the same
was true for mouse macrophages. As was seen in human
DCs, inhibition of p38MAPK or NF-κB signaling cascades
significantly lowered the amount of Hp91-stimulated IL-6
secreted from mouse macrophages (Figure 3D), further
confirming the involvement of p38MAPK and NF-κB in
Hp91 signaling.DC activation by Hp91 peptide involves signaling via a
p38 MAPK and NF-κB dependent pathway
Our previous findings have shown involvement of the
p38MAPK pathway in the HMGB1 B box-induced secre-
tion of IL-6 by human DCs [37]. Pretreatment of human
DCs with the p38MAPK inhibitor SB203580, and the NF-
κB inhibitor N-p-Tosyl-L-phenylalanine chloromethyl ke-
tone (TPCK), significantly reduced the Hp91-induced IL-6
production in DCs (Figure 4). In contrast, PD98059, a
MEK1 inhibitor, failed to significantly decrease the IL-6
production (Figure 4). The p38MAPK pathway was fur-
ther confirmed by immunoblotting for phosphorylated
p38MAPK (p-p38). p-p38 was up-regulated in mouse
BM-DCs after 40–60 min of Hp91 stimulation (Figure 3B).
In most experiments, up-regulation of p-p38 was observed
as early as 20 minutes after Hp91 stimulation. These re-
sults suggest that Hp91 induced the DC activation in a
p38MAPK and NF-κB pathway dependent manner.Figure 4 p38MAPK and NF-κB signaling are necessary for
Hp91-mediated IL-6 secretion by dendritic cells. Immature
human DCs were pre-treated for 30 min with DMSO control (D), p38
inhibitor SB203580 at 5 μM (SB5) or 20 μM (SB20), MEK1 inhibitor
PD98059 (PD) at 20 μM, or NF-κB inhibitor TPCK at 20 μM prior to
exposure to Hp91. Cell culture supernatants from the different
groups were collected after 48 h and analyzed for the presence of
IL-6 by ELISA. Results are mean (±SEM) for N = 5. *p < 0.05;
Student’s t-test.Hp91 activates IRF3 and subsequent IFNα production in
antigen presenting cells
TLR4 can signal through MyD88 dependent and inde-
pendent pathways, whereas other TLRs are MyD88-
dependent. Our data indicate that both pathways might be
involved in Hp91 signaling since a decrease in Hp91-
induced IL-6 secretion was observed for both MyD88−/−
and IFNαβR−/− knockout BM-DCs (Figure 3A). We
investigated if Hp91 activated the MyD88 independen sig-
naling pathway by investigating phosphorylation of the
downstream interferon regulatory factor 3 (IRF3) tran-
scription factor. The phosphorylation of IRF3 (pIRF3) was
up-regulated after Hp91 stimulation as early as 20 min
(Figure 3E) and at a maximum around 40 min after stimu-
lation. In addition blocking Hp91 endocytosis with dyna-
sore reduced the phosphorylation of IRF3 at 20, 40, and
60 min (Figure 3E). To further investigate involvement of
the MyD88-independent signaling pathway, we evaluated
IFN-α mRNA expression in Hp91-stimulated mouse mac-
rophages as this factor should be up-regulated by pIRF3.
Although lower than the increase induced by LPS, Hp91
induced a 99-fold increase in IFN-α mRNA levels
(Figure 3F). These findings suggest that Hp91 uptake is
required for MyD88-independent activation of the IRF3
pathway and production of IFN-α.
MyD88 signaling is not required for Hp91-elicited CTL
responses in vivo
Since Hp91 activated both the MyD88 dependent as well
as independent pathways (Figure 3A and 3E), we tested if
MyD88 was required for Hp91-induced CD8+ CTL re-
sponses in vivo. We immunized age-matched wild type
and MyD88−/− knockout mice with OVA-I (SIINFEKL)
peptide co-injected with PBS or Hp91. Both wild type and
MyD88−/− knockout mice showed similar antigen-specific
cellular immune responses, as demonstrated by increased
number of OVA-specific IFN-γ secreting cells (Figure 3G)
suggesting that induction of this antigen specific CD8+
CTL response did not require MyD88 signaling. The lack
of IL-6 secretion in MyD88−/− DCs after Hp91 exposure
indicated that Hp91 can signal through MyD88, whereas
the adjuvant effect elicited by Hp91 in vivo is MyD88
independent.
Discussion
Endogenous TLR agonists and inflammatory mediators
are attractive candidates as vaccine adjuvants, especially
for subunit vaccines that many times are poorly immuno-
genic, and the mechanism through which these types of
adjutants augment immune responses is via the innate im-
munity. There is a great need for safe and potent adju-
vants seeing that and we have previously shown that the
18 amino acid long immunostimulatory peptide Hp91, de-
rived from the B box of the HMGB1 protein, is a potent
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Th1-type immune response in vitro [32]. In addition,
Hp91 acted as adjuvant in vivo, inducing cellular immune
responses to peptide and both cellular and humoral im-
mune responses to protein antigen [33]. In this study we
characterize the mechanism of action for this adjuvant
and show here that Hp91 exerted its immunostimulatory
effects on DCs by inducing cellular uptake and activating
signaling cascades. The Hp91 peptide was taken up into
cells very rapidly via clathrin-mediated endocytosis in a
sequence specific manner. Scrambling the amino acid
sequence of Hp91 resulted in a great reduction of bind-
ing/uptake by cells, indicating that it is neither the total
charge nor total hydrophobicity that is important for
uptake rather the unique amino acid sequence. Further
characterization showed that Hp91 mediated activation
of DCs, i.e. IL-6 production in vitro, was dependent on
TLR4, MyD88, and IFNαβR, whereas MyD88 signaling
in vivo was not required for activation of CD8+ CTL
responses.
Multiple HMGB1 binding and signaling events mediate
activation of innate immune responses. The binding and
uptake of Hp91 by DCs was a rapid and sequence
dependent event and we found that the internalization
occurred via clathrin dependent endocytosis. Since
clathrin-mediated endocytosis is a receptor dependent
uptake, we explored possible receptors involved in the
uptake of Hp91. Several receptors have been implicated,
including RAGE, TLR4, TLR2, CD24/Siglec-10. HMGB1
has been shown to contribute to LPS-mediated DC mat-
uration via RAGE [18]. TLR2 and TLR4 have been shown
to be involved in HMGB1 signaling in vitro [19-23]. In
vivo data have shown binding and signaling through
TLR4 to be involved in HMGB1-induced cytokine re-
lease, i.e. inflammation leading to tissue damage in the
body [20,38].
The C-terminal motif of HMGB1 (150–183 amino
acids) is responsible for RAGE binding [38], whereas the
C-terminal end contains the TLR4 binding site. The
Hp91 peptide is located in the B box area of HMGB1
protein and contains the TLR4 binding domain and we
found that the ability to bind TLR4 was still intact in the
Hp91 peptide.
It has been shown that LPS, a TLR4 ligand, binds
TLR4, and is subsequently endocytosed together with
the receptor [35] and this seems also to be the case for
Hp91 peptide. By evaluating IL-6 secretion from knock-
out mice, we show that Hp91-stimulated activation of
DCs is dependent on TLR4 and its downstream adaptor
protein, MyD88 and further downstream signaling via
p38MAPK and NF-κB. We have previously shown the
involvement of the p38MAPK pathway in induction of
IL-6 secretion in human DCs by the HMGB1 subunit B
box [37] and others have shown that this pathway isinvolved in HMGB-1 induced activation of neutrophils
[39]. This indicates that both the HMGB1 derived pep-
tide and the whole protein have the ability to activate
the p38MAPK pathway and that the activating sequence
seems to be located within the Hp91 peptide.
Hp91 acts as adjuvant in vivo; inducing cellular immune
responses to peptide and both cellular and humoral im-
mune responses to protein antigen [33]. Immunization of
MyD88−/− mice, using Hp91 as adjuvant, induced cellular
immune responses comparable to WT mice. This suggests
that even though MyD88 was required in vitro for
Hp91-mediated IL-6 secretion in DCs, the Hp91-
induced cellular immune responses in vivo are MyD88-
independent. Furthermore, active uptake of Hp91 was
required for signaling through this MyD88-independent
pathway. Hp91 induces the in vivo production of Th1-
type cytokines, such as IL-12, and IFN-γ [33]. The Th1
cellular immune response is highly characterized by
IFN responses and we found that Hp91- induced a sig-
naling cascade activating the type I IFN pathway via
IRF3, leading to elevated expression of IFN-α mRNA.
Blocking the type I IFN receptor dampened the im-
mune response to another potential adjuvant, i.e. Poly
I:C, indicating that type I IFN play an important role in
the immune activation induced by this adjuvant [40]
Our data suggest that the activation of DCs by Hp91 is
dependent on an autocrine type I IFN feedback loop as
cells derived from IFNαβR knockout mouse failed to re-
spond. This combined with the result showing that
MyD88 was not necessary in vivo for cellular immune
responses, suggests that the MyD88-independent path-
way plays a prominent role in Hp91 induction of cellu-
lar immune responses in vivo.
These new findings provide a better understanding of
the cellular mechanisms by which the immunogenic pep-
tide induces potent immune responses. This peptide acti-
vates myeloid DCs and should be suitable as an adjuvant
in cancer immunotherapies as well as vaccines against in-
fectious diseases.
Additional file
Additional file 1: Uptake of Hp91 is temperature dependent. (A-B)
Immature human DCs were pre-cooled on ice for 30 min, then incubated
with biotinylated Hp91 (200 μg/ml) for 30 min at 4, 16, or 37°C. Cells were
permeabilized with Cytofix/Cytoperm, stained with Streptavidin-Alexa488,
and analyzed by flow cytometry. (A) Data are mean (±SEM) of N=3 and
(B) is a representative result. ***p < 0.001; Student’s t-test. Data are
mean (±SEM) of triplicate samples, but data is representative of 3 independent
experiments.
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